{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:19:30Z","timestamp":1785158370651,"version":"3.55.0"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100019734","name":"Kenya Medical Research Institute","doi-asserted-by":"crossref","award":["KEMRI\/IRG\/012\/1"],"award-info":[{"award-number":["KEMRI\/IRG\/012\/1"]}],"id":[{"id":"10.13039\/501100019734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,2,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Praziquantel alone is insufficient for the control of schistosomiasis due to poor efficacy against juvenile worms and increasing concerns about the risk of drug resistance. We compared the efficacy and safety of praziquantel combined with four different artemisinin-based combinations to praziquantel alone in treating\n              <jats:italic>Schistosoma mansoni<\/jats:italic>\n              infection in Kenyan children. In this randomized, open-label, five-arm, head-to-head, non-inferiority trial, children (aged 9\u201315 years) with\n              <jats:italic>S. mansoni<\/jats:italic>\n              infection according to duplicate Kato Katz thick smears from a stool sample in the Mwea irrigation scheme of central Kenya, were enrolled. Participants were randomly assigned (1:1:1:1:1) via a computer-generated block randomization procedure to receive a single oral dose of praziquantel (PZQ) (40 mg\/kg\/day) alone or in combination with a 3-day course (4 mg\/kg of artesunate) of artesunate plus sulfalene-pyrimethamine (As + SP), artesunate plus amodiaquine (As + AQ), artesunate plus mefloquine (As + MQ) or dihydroartemisinin-piperaquine (DHAP). Laboratory technicians were masked to treatment allocation, but participants, clinicians, and study nurses were not. The primary outcomes were the cure rate and frequency of adverse events, which were assessed 6 weeks after treatment in the available case population using a per-protocol analysis. The non-inferiority margin was set at \u221210% for the risk difference in cure rates between combination therapy and PZQ alone. Between 12 September 2018 and 11 January 2019, 540 participants were assigned to receive PZQ alone (\n              <jats:italic>n<\/jats:italic>\n              = 108), PZQ plus As + SP (\n              <jats:italic>n<\/jats:italic>\n              = 108), PZQ plus As + AQ (\n              <jats:italic>n<\/jats:italic>\n              = 108), PZQ plus As + MQ (\n              <jats:italic>n<\/jats:italic>\n              = 108), or PZQ plus DHAP (\n              <jats:italic>n<\/jats:italic>\n              = 108). Primary outcome data were available for 523 (96.9%) participants. The cure rate was 82.5% (85\/103) in PZQ alone, 81.7% (85\/104) in PZQ plus As + SP, 76.2% (80\/105) in PZQ plus As + AQ, 88.7% (94\/106) in PZQ plus As + MQ, and 85.7% (90\/105) in PZQ plus DHAP arm. Non-inferiority was declared for PZQ plus As + MQ (difference 6.2 [95% confidence interval: \u22123.3 to 15.6]) and PZQ plus DHAP (3.2 [\u22126.7 to 13.1]) but not for PZQ plus As + SP (\u22120.8 [\u221211.2 to 9.6]) or PZQ plus As + AQ (\u22126.3 [\u221217.3 to 4.6]). Adverse events were reported by 26% (138\/540) of participants, including abdominal pain, headache, and vomiting. There were no serious adverse events. Alternatives to praziquantel should include praziquantel plus artesunate-mefloquine or praziquantel plus dihydroartemisinin-piperaquine. However, further multicentre trials are needed in different epidemiological settings and population groups to confirm these findings.\n            <\/jats:p>\n            <jats:sec>\n              <jats:title>CLINICAL TRIALS<\/jats:title>\n              <jats:p>\n                This study is registered with the Pan-African Clinical Trials Registry under\n                <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"PACTR202001919442161\" document-id-type=\"clinical-trial-number\" source-id=\"PACTR\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=9591\">PACTR202001919442161<\/jats:related-object>\n                .\n              <\/jats:p>\n            <\/jats:sec>\n          <\/jats:sec>","DOI":"10.1128\/aac.00739-24","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T14:06:19Z","timestamp":1734617179000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with\n            <i>Schistosoma mansoni<\/i>\n            infection: open-label, randomized, head-to-head, non-inferiority trial"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0741-8533","authenticated-orcid":true,"given":"Charles O.","family":"Obonyo","sequence":"first","affiliation":[{"name":"Centre for Global Health Research, Kenya Medical Research Institute","place":["Kisumu, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent O.","family":"Were","sequence":"additional","affiliation":[{"name":"Centre for Global Health Research, Kenya Medical Research Institute","place":["Kisumu, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wamae","sequence":"additional","affiliation":[{"name":"Centre for Global Health Research, Kenya Medical Research Institute","place":["Kisumu, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick M. O.","family":"Muok","sequence":"additional","affiliation":[{"name":"Centre for Global Health Research, Kenya Medical Research Institute","place":["Kisumu, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61949-2"},{"key":"e_1_3_4_3_2","first-page":"621","article-title":"Schistosomiasis and soil-transmitted helminthiases: progress report, 2021","volume":"97","author":"WHO","year":"2022","unstructured":"WHO. 2022. Schistosomiasis and soil-transmitted helminthiases: progress report, 2021. Wkly Epidemiol Rec 97:621\u2013632. https:\/\/iris.who.int\/handle\/10665\/364997.","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32335-3"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00066-3"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182009000493"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/151.6.1130"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4922(01)02209-7"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00090-6"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000504"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1999.60.932"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph11010015"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules190915058"},{"key":"e_1_3_4_14_2","first-page":"105","article-title":"Artemisinins for schistosomiasis and beyond","volume":"8","author":"Utzinger J","year":"2007","unstructured":"Utzinger J, Shu-Hua X, Tanner M, Keiser J. 2007. Artemisinins for schistosomiasis and beyond. Curr Opin Invest Drug 8:105\u2013116. https:\/\/pubmed.ncbi.nlm.nih.gov\/17328226.","journal-title":"Curr Opin Invest Drug"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.02.017"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1487-1495.2003"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2006.03.007"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045867"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008619"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002975"},{"key":"e_1_3_4_21_2","unstructured":"WHO. 2015. Guidelines for the treatment of malaria. Geneva: World Health Organization. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/162441. Retrieved 12 May 2024."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047147"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3487183"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2009.01.026"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006732"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70161-4"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/651682"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02719-4"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003286"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2000.00646.x"},{"key":"e_1_3_4_31_2","unstructured":"WHO. 2013. Assessing the efficacy of anthelminthic drugs against schistosomiasis and soil-transmitted infections. Geneva World Health Organization"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005372"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1995.53.167"},{"key":"e_1_3_4_34_2","first-page":"499","article-title":"Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya","volume":"73","author":"Jaoko WG","year":"1996","unstructured":"Jaoko WG, Muchemi G, Oguya FO. 1996. Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. East Afr Med J 73:499\u2013501. https:\/\/pubmed.ncbi.nlm.nih.gov\/8898462.","journal-title":"East Afr Med J"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003821"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2011.04.003"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.3c00081"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-1991-z"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07790-3"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2903-2904.2000"},{"key":"e_1_3_4_41_2","first-page":"397","article-title":"A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni","volume":"14","author":"Katz N","year":"1972","unstructured":"Katz N, Chaves A, Pellegrino J. 1972. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 14:397\u2013400. https:\/\/pubmed.ncbi.nlm.nih.gov\/4675644","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"e_1_3_4_42_2","unstructured":"World Health Organization. 2002. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: a report of WHO expert committee (WHO technical report series 912). Geneva: World Health Organization"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2009.02234.x"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0325"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00739-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00739-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:07:00Z","timestamp":1739459220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00739-24"}},"subtitle":[],"editor":[{"given":"Audrey","family":"Odom John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,13]]}},"alternative-id":["10.1128\/aac.00739-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00739-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"2024-05-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00739-24"}}